Profound Medical Announces First Prostate Cancer Patient Treated With TULSA-PRO At Mount Sinai Hospital

Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function

The Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World Report® for 2025-26

TORONTO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce the world-renowned Mount Sinai Hospital has successfully treated its first prostate cancer patient with the TULSA-PRO® system.